Natural Ergot Alkaloids in Ocular Pharmacotherapy: Known Molecules for Novel Nanoparticle-Based Delivery Systems
Open Access
- 30 June 2020
- journal article
- review article
- Published by MDPI AG in Biomolecules
- Vol. 10 (7), 980
- https://doi.org/10.3390/biom10070980
Abstract
Several pharmacological properties are attributed to ergot alkaloids as a result of their antibacterial, antiproliferative, and antioxidant effects. Although known for their biomedical applications (e.g., for the treatment of glaucoma), most ergot alkaloids exhibit high toxicological risk and may even be lethal to humans and animals. Their pharmacological profile results from the structural similarity between lysergic acid-derived compounds and noradrenalin, dopamine, and serotonin neurotransmitters. To reduce their toxicological risk, while increasing their bioavailability, improved delivery systems were proposed. This review discusses the safety aspects of using ergot alkaloids in ocular pharmacology and proposes the development of lipid and polymeric nanoparticles for the topical administration of these drugs to enhance their therapeutic efficacy for the treatment of glaucoma.Keywords
This publication has 134 references indexed in Scilit:
- Nanotechnology and glaucomaCurrent Opinion in Opthalmology, 2013
- Permeability of ergot alkaloids across the blood‐brain barrier in vitro and influence on the barrier integrityMolecular Nutrition & Food Research, 2011
- Release profile and transscleral permeation of triamcinolone acetonide loaded nanostructured lipid carriers (TA-NLC): in vitro and ex vivo studiesNanomedicine: Nanotechnology, Biology and Medicine, 2011
- Cytotoxicity and accumulation of ergot alkaloids in human primary cellsToxicology, 2011
- Optimizing flurbiprofen-loaded NLC by central composite factorial design for ocular deliveryNanotechnology, 2010
- A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular deliveryEuropean Journal of Pharmaceutics and Biopharmaceutics, 2010
- Lipid Nanoparticles (SLN®, NLC®) for Cutaneous Drug Delivery:Structure, Protection and Skin EffectsJournal of Biomedical Nanotechnology, 2007
- BROMOCRIPTINE EYEDROPS LOWER INTRAOCULAR PRESSURE WITHOUT AFFECTING PROLACTIN LEVELSThe Lancet, 1984
- The Effect of Topically Used Hydergine® on Ocular TensionOphthalmologica, 1964
- Experimental and Therapeutic Investigations With Certain New Hydrogenated Ergot Alkaloids in Peripheral Vascular DisordersAngiology, 1950